Quantcast

Latest Imatinib Stories

2008-06-22 15:00:28

ANN ARBOR, Mich., June 22 /PRNewswire-USNewswire/ -- For over a decade, the drug called tPA has proven its worth as the most effective emergency treatment for the most common kind of stroke. But its promise is blemished by two facts: tPA can cause dangerous bleeding in the brain, and its brain-saving power fades fast after the third hour of a stroke. Now, a new paper published online in Nature Medicine reveals why tPA has these limitations. It also gives tantalizing evidence about how...

2008-06-16 12:01:05

Exelixis has reported preliminary Phase I data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib. Approximately 17 subjects have received at least one dose of XL228, of whom 16 had completed cycle 1. The trial is evaluating a treatment cycle consisting of four weekly one-hour IV infusions of XL228 at doses...

2008-06-16 09:01:19

ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibitors (TKIs). These data represent the first findings to be presented from this ongoing study, conducted in patients with or without BCR-ABL mutations. The data presented complement the...

2008-06-09 06:00:38

Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, today announced that Portland, Ore.-based Oregon Health & Science University (OHSU) Cancer Institute has purchased a MassARRAY(R) system for use in the discovery, development and testing of biomarker panels for rapid classification and characterization of cancer. The OHSU Cancer Institute is recognized worldwide for its cancer research. "This placement at the prestigious OHSU Cancer Institute is a tremendous...

2008-06-05 03:00:07

By Edwards, Michael A Beatty, John S; Shah, Malay B; Bittner, James G IV To the Editor: Non-epithelial mesenchymal tumors, including gastrointestinal stromal tumors (GISTs) and smooth muscle tumors (SMTs), are rare and may occur in any part of the alimentary tract.1 GISTs originate from the interstitial cell of Cajal, an intestinal pacemaker cell, and represent 1 per cent to 3 per cent of all gastrointestinal malignant tumors. Approximately 5 per cent of GISTs occur in the colon and rectum...

632e85fdf2a7b2b8406f7bac0448b4db
2008-03-06 10:30:00

According to new research, use of the cancer drug Gleevec may cause fertility complications in some women.Dr. Constantinos Christopoulos of the Amalia Fleming General Hospital in Athens and colleagues published the recent study of the drug, generically known as imatinib, in the New England Journal of Medicine. The team studied the case of a 30-year-old woman with chronic myeloid leukemia (CML). After taking Gleevec for two years, the woman stopped menstruating. They also noted a reduction of...

2007-05-18 06:00:37

By Patnaik, Mrinal M; Rindos, Michelle; Kouides, Peter A; Tefferi, Ayalew; Pardanani, Animesh Context.-Systemic mastocytosis is characterized by abnormal growth and accumulation of neoplastic mast cells in various organs. The clinical presentation is varied and may include skin rash, symptoms related to release of mast cell mediators, and/or organopathy from involvement of bone, liver, spleen, bowel, or bone marrow. Objective.-To concisely review pathogenesis, disease classification,...

2006-12-06 18:02:44

By ED SUSMAN After five years of treatment nearly 90 percent of leukemia patients treated with Gleevec are still alive -- an outcome barely conceivable before the drug was discovered. The Gleevec story truly is a triumph of science over disease, Brian Druker, the lead investigator of the studies with the anti-cancer drug, told United Press International Wednesday. Druker, professor of medicine at the Oregon Health and Sciences University Cancer Center in Portland, said, The results we...

2006-07-23 14:45:00

By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - Gleevec, the pill that transformed cancer treatments by offering an easy way to target a difficult type of leukemia, may cause serious heart damage, researchers cautioned on Sunday. They found evidence that treatment caused heart failure in 10 patients who took Gleevec, made by Swiss drugmaker Novartis. Patients should not stop taking the drug, known generically as imatinib, but should be watched closely for heart damage,...

89d7ddf2b7a291cf1da22844fcc1d77b1
2006-07-23 12:05:00

By Maggie Fox, Health and Science Correspondent WASHINGTON -- Gleevec, the pill that transformed cancer treatments by offering an easy way to target a difficult type of leukemia, may cause serious heart damage, researchers cautioned on Sunday. They found evidence that treatment caused heart failure in 10 patients who took Gleevec, made by Swiss drugmaker Novartis. Patients should not stop taking the drug, known generically as imatinib, but should be watched closely for heart damage, the team...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related